Related Experiment Video
Updated: Feb 2, 2026

Lipid Supplementation for Longevity and Gene Transcriptional Analysis in Caenorhabditis elegans
Published on: December 9, 2022
Dose-Dependent Effects of FKRP Gene-Replacement Therapy on Functional Rescue and Longevity in Dystrophic Mice
Charles Harvey Vannoy1, Victoria Leroy1, Qi Long Lu1
1McColl-Lockwood Laboratory for Muscular Dystrophy Research, Carolinas Medical Center, Atrium Health, Charlotte, NC 28203, USA.
Abstract:
Muscular dystrophy-dystroglycanopathies (MDDGs) resulting from fukutin-related protein (FKRP) gene mutations are rare disorders that result in a wide spectrum of clinical severity based on the age of onset, the degree of myogenic atrophy, and/or neurologic involvement. There is no cure for any of the FKRP-related disorders, and few options are available for symptom management. Herein, we examine the longitudinal effects of a dose-escalation study to evaluate the safety and therapeutic potential of FKRP gene-replacement therapy in a p.P448L (FKRPP448L) mouse model of MDDG. A recombinant adeno-associated virus (AAV) serotype 9 vector expressing human FKRP (AAV9-FKRP) was systemically administered to FKRPP448L mice at 5 weeks of age, when early onset of the disease is evidenced. A comprehensive analysis of protein and gene expression, histopathology, skeletal muscle function, and cardiorespiratory function was performed over short (9-week) and/or long-term (52-week) study periods. Additional studies assessed the impact of FKRP gene-replacement therapy on lifespan at an advanced stage of disease progression. Results indicate that treatment intervention can restore the biochemical defects in a dose-dependent manner, with potential for improvement in the trajectory of disease progression and extension of the expected lifespan. This study supports the initiation of early-stage clinical trials for FKRP-related disorders.
Insights
FKRP gene-replacement therapy shows promise for muscular dystrophy-dystroglycanopathies (MDDGs). This study in FKRP-mutant mice demonstrated dose-dependent restoration of biochemical defects and improved lifespan, supporting clinical trials.
Area of Science:
- Genetics and Molecular Biology
- Neurology
- Regenerative Medicine
Background:
- Muscular dystrophy-dystroglycanopathies (MDDGs) caused by FKRP gene mutations present a spectrum of severity with limited treatment options.
- FKRP-related disorders lack a cure, necessitating exploration of novel therapeutic strategies for symptom management and disease modification.
Purpose of the Study:
- To evaluate the safety and therapeutic potential of FKRP gene-replacement therapy using an AAV9 vector in a mouse model of FKRP-related MDDG.
- To assess the longitudinal effects of dose-escalation gene therapy on biochemical, histopathological, functional, and lifespan outcomes.
Main Methods:
- Systemic administration of AAV9-FKRP to FKRP P448L mice at 5 weeks of age.
- Comprehensive analysis of protein/gene expression, histopathology, skeletal muscle, and cardiorespiratory function over 9 and 52 weeks.
- Lifespan assessment in an advanced disease stage model.
Main Results:
- FKRP gene-replacement therapy restored biochemical defects in a dose-dependent manner.
- Treatment showed potential for improving disease progression trajectory and extending lifespan.
- Histopathological and functional improvements were observed, supporting therapeutic efficacy.
Conclusions:
- Early-stage FKRP gene-replacement therapy is safe and therapeutically beneficial in a mouse model of FKRP-related MDDG.
- Dose-dependent restoration of FKRP function offers a promising avenue for treating these rare neuromuscular disorders.
- These findings provide a strong rationale for initiating clinical trials in patients with FKRP-related disorders.
More Related Videos
09:40Characterization of Functionally Associated miRNAs in Glioblastoma and their Engineering into Artificial Clusters for Gene Therapy
Published on: October 4, 2019
08:13Purification and Transplantation of Myogenic Progenitor Cell Derived Exosomes to Improve Cardiac Function in Duchenne Muscular Dystrophic Mice
Published on: April 10, 2019
Related Concept Videos
Gene Therapy
Continuous Renal Replacement Therapy
Insulin: Dosing Regimen and Adverse Effects
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance
A study on guinea pigs examined the...
Extracorporeal Removal of Drugs: Continuous Renal Replacement Therapy
Biological Effects of Radiation